Decreased cGMP level contributes to increased contraction in arteries from hypertensive rats: role of phosphodiesterase 1
about
Role of Phosphodiesterase 5 and Cyclic GMP in HypertensionTSPO-specific ligand vinpocetine exerts a neuroprotective effect by suppressing microglial inflammationAnti-atherogenic properties of resveratrol: 4-week resveratrol administration associated with serum concentrations of SIRT1, adiponectin, S100A8/A9 and VSMCs contractility in a rat model.Inhibition of phosphodiesterase 5 restores endothelial function in renovascular hypertension.Phosphodiesterase 5 attenuates the vasodilatory response in renovascular hypertensionSoluble guanylyl cyclase is a target of angiotensin II-induced nitrosative stress in a hypertensive rat model.Traumatic Brain Injury Upregulates Phosphodiesterase Expression in the Hippocampus.Suppression of endoplasmic reticulum stress improves endothelium-dependent contractile responses in aorta of the spontaneously hypertensive ratGene-centric meta-analysis in 87,736 individuals of European ancestry identifies multiple blood-pressure-related loci.PDE1 isozymes, key regulators of pathological vascular remodelingAlterations in vasoconstrictor responses to the endothelium-derived contracting factor uridine adenosine tetraphosphate are region specific in DOCA-salt hypertensive ratsChemerin reduces vascular nitric oxide/cGMP signalling in rat aorta: a link to vascular dysfunction in obesity?PDE1A inhibition elicits cGMP-dependent relaxation of rat mesenteric arteries.Novel selective PDE type 1 inhibitors cause vasodilatation and lower blood pressure in rats.An update on vinpocetine: New discoveries and clinical implications.Differential effects of long-term slow-pressor and subpressor angiotensin II on contractile and relaxant reactivity of resistance versus conductance arteries.
P2860
Q26748049-DE86DFB0-4EFB-4052-BD6C-9BC1F254CFADQ28272695-45030404-3B98-4A59-B231-63B0C0D48926Q33724276-EA5B32C5-2936-4653-A2DC-AC2F5612A068Q34234143-50C6EB21-B4AB-47B4-ABFE-3F535D4BDCA2Q35049171-885BB842-EB71-4960-B99A-BA6910E7BEC8Q36309312-CE5FC085-5D09-44EE-AAB0-2A95FA6BF5AEQ36548551-F00DD135-53E1-45A4-9262-0E839BC8CE0AQ37093720-6A455BBD-B4B9-4305-8D7A-DC471E0064CCQ37634121-97539C7D-62EF-418B-A14C-FE4F723DBA07Q37941150-C9A6074B-7B61-4999-BC38-5DEFF10AED2AQ40617162-688028A3-6C38-4A6B-BA9B-8FDA874F3FA7Q46935958-670C6A64-CEC6-41F3-8B66-1FA20B9FB46BQ48345105-87689AE7-8C8E-4597-95B3-1F115FBD9119Q48370513-68584A53-BFDC-4C21-BA39-33596F138A44Q49567493-E9124562-9BDF-445F-8988-B66D79500EAFQ52674620-3C54CB13-3FDE-4A94-A067-C58088CC5ED3
P2860
Decreased cGMP level contributes to increased contraction in arteries from hypertensive rats: role of phosphodiesterase 1
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Decreased cGMP level contribut ...... s: role of phosphodiesterase 1
@ast
Decreased cGMP level contribut ...... s: role of phosphodiesterase 1
@en
Decreased cGMP level contribut ...... s: role of phosphodiesterase 1
@nl
type
label
Decreased cGMP level contribut ...... s: role of phosphodiesterase 1
@ast
Decreased cGMP level contribut ...... s: role of phosphodiesterase 1
@en
Decreased cGMP level contribut ...... s: role of phosphodiesterase 1
@nl
prefLabel
Decreased cGMP level contribut ...... s: role of phosphodiesterase 1
@ast
Decreased cGMP level contribut ...... s: role of phosphodiesterase 1
@en
Decreased cGMP level contribut ...... s: role of phosphodiesterase 1
@nl
P2093
P2860
P1433
P1476
Decreased cGMP level contribut ...... s: role of phosphodiesterase 1
@en
P2093
Fernanda R Giachini
R Clinton Webb
Victor V Lima
P2860
P304
P356
10.1161/HYPERTENSIONAHA.110.164327
P407
P577
2011-01-31T00:00:00Z